Avid Bioservices Inc (CDMO)

[biopharm]

looks like LabCorp (and which bought Covance) could use PS Targeting patents and related Biomarkers to shore up their future collaborations with BMS.

Hopefully CEO Roger Lias still has his contacts at Covance handy....because Covance would likely see the value in PS Targeting IP and Exosomes related Biomarkers....more than just residual values.

Quote:
FRI SEP 2, 2016 / 7:28 AM EDT
Judge invalidates LabCorp unit's genetic testing patents

A federal judge has invalidated four patents on genetic tests to be used in cancer treatment belonging to a Laboratory Corporation of America Holdings unit, finding they claimed unpatentable laws of nature.

The ruling, handed down Wednesday by U.S. District Judge Allison Burroughs in Boston, is a victory for German diagnostics company Qiagen NV, which had challenged the patents. It follows an order from Burroughs in the same case last September invalidating a similar patent on the same grounds.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2bVuGx8


https://www.google.com/amp/mobile.reuters.com/article/amp/idUSL1N1BE0D4

So much going on behind the scenes regards to patents ...

Who gains control of the PS Targeting patents, because there are hundreds of blood tests on hundreds of conditions and since flipped PS detections are not standing still, it can be captured via meeical device implants, forwarded to ones Apple watch and further forwarded to MDs that can analyze those PS Targeting Biomarkers

UTSWM must like the idea of receiving back exosome research from Peregrine that collaborated on such data and those collaborations mean much more after judge rules just this week that any such collaboration could spark some fireworks around the BOD table at Avid Bioservices which may be proven to have immediate fiduciary duties to protect PS Targeting patents, especially if Oncologie paid for delay